|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FRRS1 |
Gene summary for FRRS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FRRS1 | Gene ID | 391059 |
| Gene name | ferric chelate reductase 1 | |
| Gene Alias | SDFR2 | |
| Cytomap | 1p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | Q6ZNA5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 391059 | FRRS1 | CCI_1 | Human | Cervix | CC | 1.96e-04 | 6.46e-01 | 0.528 |
| 391059 | FRRS1 | CCI_2 | Human | Cervix | CC | 4.04e-03 | 5.05e-01 | 0.5249 |
| 391059 | FRRS1 | CCI_3 | Human | Cervix | CC | 2.31e-14 | 6.73e-01 | 0.516 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00550726 | Cervix | CC | iron ion homeostasis | 19/2311 | 85/18723 | 6.88e-03 | 3.74e-02 | 19 |
| GO:00550768 | Cervix | CC | transition metal ion homeostasis | 27/2311 | 138/18723 | 9.89e-03 | 4.85e-02 | 27 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FRRS1 | SNV | Missense_Mutation | rs376478764 | c.1091C>A | p.Ser364Tyr | p.S364Y | Q6ZNA5 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| FRRS1 | SNV | Missense_Mutation | rs745630104 | c.1853N>T | p.Ser618Leu | p.S618L | Q6ZNA5 | protein_coding | deleterious_low_confidence(0.05) | benign(0) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| FRRS1 | SNV | Missense_Mutation | c.1070N>T | p.Ser357Phe | p.S357F | Q6ZNA5 | protein_coding | tolerated(0.7) | benign(0.001) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| FRRS1 | SNV | Missense_Mutation | c.1469N>A | p.Arg490Lys | p.R490K | Q6ZNA5 | protein_coding | tolerated(0.31) | benign(0.084) | TCGA-EW-A1P6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| FRRS1 | SNV | Missense_Mutation | novel | c.148N>A | p.Asp50Asn | p.D50N | Q6ZNA5 | protein_coding | tolerated(0.64) | benign(0) | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| FRRS1 | insertion | In_Frame_Ins | novel | c.709_710insATTCTCACTCAT | p.Gly237delinsAspSerHisSerCys | p.G237delinsDSHSC | Q6ZNA5 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| FRRS1 | insertion | Nonsense_Mutation | novel | c.708_709insAGAAGGCAGCATTTATTTTAAGCC | p.Ser236_Gly237insArgArgGlnHisLeuPheTerAla | p.S236_G237insRRQHLF*A | Q6ZNA5 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| FRRS1 | deletion | Frame_Shift_Del | c.833delN | p.Arg278GlnfsTer5 | p.R278Qfs*5 | Q6ZNA5 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | |||
| FRRS1 | insertion | Nonsense_Mutation | novel | c.584_585insAGAGTGAG | p.Ser196GlufsTer2 | p.S196Efs*2 | Q6ZNA5 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
| FRRS1 | insertion | In_Frame_Ins | novel | c.583_584insAGCCAAGATTGTGCCACTGCACTCCAGCCTGGGCGA | p.Ala195delinsGluProArgLeuCysHisCysThrProAlaTrpAlaThr | p.A195delinsEPRLCHCTPAWAT | Q6ZNA5 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |